Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
National Institutes of Health Clinical Center (CC)
PMV Pharmaceuticals, Inc
Mayo Clinic
Kivu Bioscience Inc.
ViroMissile, Inc.
Memorial Sloan Kettering Cancer Center
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
ALX Oncology Inc.
Clasp Therapeutics, Inc.
BioNTech SE
Eli Lilly and Company
MacroGenics
Solve Therapeutics
Eli Lilly and Company
Kidney Cancer Research Bureau
M.D. Anderson Cancer Center
OncoNano Medicine, Inc.
GlaxoSmithKline
VM Oncology, LLC
Memorial Sloan Kettering Cancer Center
University of Chicago
Therorna
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Sun Yat-sen University
GI Innovation, Inc.
Nurix Therapeutics, Inc.
Memgen, Inc.
Yuhan Corporation
University of Wisconsin, Madison
AVEO Pharmaceuticals, Inc.
Affiliated Hospital of Nantong University
Sun Yat-sen University
CJ Bioscience, Inc.
Nykode Therapeutics ASA
Pack Health
UNICANCER
Taiho Pharmaceutical Co., Ltd.
Centre hospitalier de l'Université de Montréal (CHUM)
Eye & ENT Hospital of Fudan University
Sun Yat-sen University